Home › Funds › Bain Capital Life Sciences Investors, LLC › SVRA
Bain Capital Life Sciences Investors, LLC position in SVRA
SAVARA INC · Health Care
Bain Capital Life Sciences Investors, LLC reported holding 17,600,621 shares of SVRA (SAVARA INC) in its Q3 2026 13F filing — a position valued at US$90.8M, representing 6.25% of its reported portfolio and ranking #6 among its reported holdings. Bain Capital Life Sciences Investors, LLC has disclosed SVRA holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Bain Capital Life Sciences Investors, LLC's SVRA position evolved
Bain Capital Life Sciences Investors, LLC first disclosed a stake in SVRA in Q3 2023 at 14,232,751 shares (US$53.8M). The position peaked in Q2 2026 at 17,600,621 shares, worth US$108.4M. Across 13 filings, Bain Capital Life Sciences Investors, LLC increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 10 time(s). The most recent filing (Q3 2026) shows 17,600,621 shares valued at US$90.8M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 14.23M | $53.80M | New |
| Q4 2023 | 14.23M | $66.89M | Hold |
| Q1 2024 | 14.57M | $72.54M | Add |
| Q2 2024 | 14.57M | $58.70M | Hold |
| Q3 2024 | 14.57M | $61.76M | Hold |
| Q4 2024 | 14.57M | $44.72M | Hold |
| Q1 2025 | 17.60M | $48.75M | Add |
| Q2 2025 | 17.60M | $40.13M | Hold |
| Q3 2025 | 17.60M | $62.83M | Hold |
| Q4 2025 | 17.60M | $106.13M | Hold |
| Q1 2026 | 17.60M | $96.10M | Hold |
| Q2 2026 | 17.60M | $108.42M | Hold |
| Q3 2026 | 17.60M | $90.82M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SVRA and 13F data
SVRA (SAVARA INC) is a Health Care company. 38 other funds we track also report a position in SVRA — the largest reported positions include NEA Management Company, LLC (US$150.7M), Venrock Adviser, LLC (US$90.8M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$83.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SVRA
- NEA Management Company, LLC 24.47M sh · $150.74M · Q2 2026
- Venrock Adviser, LLC 14.75M sh · $90.84M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 13.57M sh · $83.59M · Q2 2026
- TCG Crossover Management, LLC 12.36M sh · $63.79M · Q3 2026
- Frazier Life Sciences Management, L.P. 9.72M sh · $59.88M · Q2 2026
- Nantahala Capital Management, LLC 7.14M sh · $36.83M · Q3 2026
- Spruce Street Capital LP 5.38M sh · $27.77M · Q3 2026
- Vestal Point Capital, LP 2.72M sh · $16.76M · Q2 2026
- Rosalind Advisors, Inc. 3.18M sh · $16.40M · Q3 2026
- Affinity Asset Advisors, LLC 2.51M sh · $12.96M · Q3 2026
- NAN FUNG TRINITY (HK) Ltd 1.84M sh · $9.51M · Q3 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 1.52M sh · $7.84M · Q3 2026
More on Bain Capital Life Sciences Investors, LLC
FAQ
How long has Bain Capital Life Sciences Investors, LLC held SVRA?
Bain Capital Life Sciences Investors, LLC has disclosed SVRA holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Bain Capital Life Sciences Investors, LLC's current position in SVRA?
As of Q3 2026, Bain Capital Life Sciences Investors, LLC holds 17.60M shares of SVRA (SAVARA INC), valued at $90.82M, representing 6.25% of its reported portfolio and ranking #6.
Has Bain Capital Life Sciences Investors, LLC been buying or selling SVRA?
In the latest 13F filing (Q3 2026), Bain Capital Life Sciences Investors, LLC held unchanged its position in SVRA. The position peaked in Q2 2026 at 17.60M shares.
Which other funds hold SVRA?
Other major institutional holders of SVRA include NEA Management Company, LLC, Venrock Adviser, LLC, DEERFIELD MANAGEMENT COMPANY, L.P., among 38 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.